SuperworthCollegium Pharmaceutical EPS COLL
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- $1.24
- Latest quarter, Q2 FY26
- −$0.46
- −235% on a year earlier
- Fiscal year 2025
- $1.71
- −8% on the year before
Collegium Pharmaceutical's earnings per share was $1.24 over the twelve months to Jun 30, 2026, up 19% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.46, down 235% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 18% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.71 | −8% |
| FY2024 | $1.86 | +58% |
| FY2023 | $1.18 | n/a |
| FY2022 | −$0.74 | −144% |
| FY2021 | $1.69 | +122% |
| FY2020 | $0.76 | n/a |
| FY2019 | −$0.68 | n/a |
| FY2018 | −$1.19 | n/a |
| FY2017 | −$2.50 | n/a |
| FY2016 | −$3.88 | n/a |
| FY2015 | −$1.86 | n/a |
| FY2014 | −$22.71 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.46 | −235% | $1.24 | |
| Q1 FY26 | $0.40 | +471% | $2.04 | |
| Q4 FY25 | $0.46 | +28% | $1.71 | |
| Q3 FY25 | $0.84 | +211% | $1.61 | |
| Q2 FY25 | $0.34 | −35% | $1.04 | |
| Q1 FY25 | $0.07 | −90% | $1.22 | |
| Q4 FY24 | $0.36 | −56% | $1.86 | |
| Q3 FY24 | $0.27 | −49% | $2.32 | |
| Q2 FY24 | $0.52 | +53% | $2.58 | |
| Q1 FY24 | $0.71 | n/a | $2.40 | |
| Q4 FY23 | $0.82 | n/a | $1.18 | |
| Q3 FY23 | $0.53 | +5200% | $0.15 |
Against its peers
Companies in Drug Manufacturers - General nearest Collegium Pharmaceutical's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| ARVNArvinas | $0.16 | |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| Peer median | $0.85 |
Where Collegium Pharmaceutical ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Collegium Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.